PARIS — "Everyone says there are 60 new systems for renal denervation, but where are they?" asked Mano Iyer, a founder of ReCor Medical (Menlo Park, California) saying he only counts five with a CE mark, so where are the other 55? Iyer has a right to feel confident about the growing strength of his company with a CE Mark and a 50-patient post-market study underway in Europe for one of the most novel systems for renal denervation, the newest device-based treatment category.